Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone in Comorbid Alcohol Use Disorder and ADHD
NCT03904498Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Aug 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolcapone in alcohol use disorder (AUD) and attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Change in alcohol-induced stimulation between medication periods, Change in subjective response to alcohol between medication periods and 4 more. Started Aug 2021; status: completed.
02
Drugs
tolcapone
03
Conditions
alcohol use disorder (AUD)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03904498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904498.